Glenmark Pharmaceuticals' (NSE:GLENMARK, BOM:532296) US-based arm Glenmark Pharmaceuticals Inc has launched its drug Clindamycin Phosphate Foam, 1%, according to a Wednesday filing to the Indian stock exchanges.
Glenmark's Clindamycin Phosphate Foam, 1%, is bioequivalent and therapeutically equivalent to Mylan Pharmaceuticals' reference listed drug Evoclin Foam, 1%.
Clindamycin Phosphate Foam is a topical treatment for acne, according to the company website.
Shares of the company were down over 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.